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Abstract 1 
The generation of bioengineered biliary tissue could contribute to the management of some of 2 
the most impactful cholangiopathies associated with liver transplantation, such as biliary 3 
atresia or ischemic cholangiopathy. Recent advances in tissue engineering and in vitro 4 
cholangiocyte culture have made the achievement of this goal possible. Here we provide an 5 
overview of these developments and review the progress towards the generation and 6 
transplantation of bioengineered bile ducts.  7 
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1. Introduction 1 
Bile duct disease accounts for approximately one third of adult and 70% of pediatric liver 2 
transplants [1], [2]. Several of these disorders are anatomically diffuse and affect the small 3 
branches of the intrahepatic bile ducts that are not amenable to surgical replacement or 4 
reconstruction. However, some of the most impactful cholangiopathies that require, or are a 5 
consequence of, liver transplantation can be limited to the large ducts of the extrahepatic 6 
biliary tree. These include biliary atresia, which constitutes the leading cause for pediatric liver 7 
transplantation [1], [3] and dominant ischemic strictures, which after rejection, represent one 8 
of the most common causes of liver transplant failure [4]. Surgical replacement of the affected 9 
bile ducts is a potentially effective treatment, but is currently hampered by the lack of suitable 10 
healthy tissue. Portoenterostomy, which entails using a length of small intestine as a conduit 11 
to enable bile flow from the liver to the gut, can be used as an alternative treatment. 12 
Portoenterostomy, however, is associated with complications such as reflux cholangitis and 13 
stricture formation [5]. Furthermore, it is not curative for the majority of the patients with biliary 14 
atresia, who will proceed to need liver transplantation later in life [6]. 15 
Tissue engineering could address the lack of primary tissue by combining cells, materials and 16 
growth stimulating signals [7] to generate bioengineered bile ducts. Indeed, biliary tissue 17 
generated in vitro could provide a viable alternative for the management of common bile duct 18 
(CBD) disorders and potentially reduce the need for organ transplantation. However, despite 19 
the significant progress in tissue engineering for many other organs over the last decade, the 20 
generation of functional bile ducts in vitro has been hindered by a number of challenges. More 21 
specifically, until recently there was a lack of robust culture systems for growing biliary 22 
epithelial cells, which constitute the main functional cell population in the bile duct [8], [9]. 23 
Furthermore, the biliary system is very sensitive to ischemia necessitating the development of 24 
fully vascularized constructs to ensure adequate supply of nutrients and oxygen [4]. Over the 25 
last few years, there have been several breakthroughs in these fields leading to the first 26 
studies of functional bioengineered bile duct transplantation. Here we provide a summary of 27 
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these developments and review the progress towards the generation and transplantation of 1 
bioengineered bile ducts.  2 
 3 
2. Cell types 4 
2.1 Cholangiocytes 5 
The primary function of the bile duct is unobstructed transport of bile, which is a toxic fluid, 6 
from the liver to the intestinal lumen [10], [11]. Cholangiocytes form an epithelial monolayer 7 
lining the lumen of the bile duct (Figure 1). They are responsible for providing a barrier against 8 
the toxic effects of bile on other cells within the duct, transferring water, electrolytes and bile 9 
acids and modifying the composition of bile [10]. Because this a pivotal role for the function 10 
and integrity of the biliary tree, cholangiocytes are crucial for the generation of bioengineered 11 
bile ducts.  12 
Historically the biliary epithelium has proven difficult to access and in vitro propagation of 13 
cholangiocytes has remained challenging. To overcome these issues multiple groups have 14 
used human Induced Pluripotent Stem Cells (hIPSCs). hIPSCs can be easily derived from 15 
multiple readily-accessible tissues such as skin or peripheral blood lymphocytes and 16 
differentiated into almost any somatic cell type [12] including the biliary epithelium [13]–[17]. 17 
The resulting cholangiocytes express key biliary markers [13]–[16] and sustain functional 18 
properties of their in vivo counterparts [13]–[16]. Furthermore they can be genetically 19 
manipulated to generate patient lines in which genetic defects have been corrected [13], 20 
thereby providing a source of healthy autologous biliary epithelium. However, hIPSC-derived 21 
cholangiocytes also have limitations: The resulting cells are not fully mature but retain fetal 22 
characteristics [13]–[16] and successful orthotopic transplantation and repopulation of the 23 
biliary tree has not been demonstrated so far [13]–[16]. Moreover, the biliary epithelium 24 
generated corresponds to intrahepatic cholangiocytes [13]–[16] and generation of 25 
cholangiocytes lining the lumen of the extrahepatic bile ducts has not been reported.   26 
To address these challenges, an organoid culture system has been developed to enable 27 
successful in vitro propagation of primary cholangiocytes derived from the CBD or the 28 
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gallbladder [18]. The resulting organoids sustain the function and genetic profile of 1 
extrahepatic cholangiocytes, survive in vivo, self-organize into tubular structures and can be 2 
used to reconstruct the biliary epithelium following transplantation [18]. However, some 3 
limitations still exist. In depth studies are required to elucidate the extent to which removing 4 
these cells from their niche and propagating them in vitro impacts on their properties. 5 
Furthermore, genetic modification of organoids is possible but remains more complicated 6 
compared to cells grown in monolayers. Finally, access is more limited compared to hIPSCs 7 
rendering the generation of autologous lines more difficult, although the use of gallbladder 8 
tissue, accessed by surgical cholecystectomy, could resolve some of these issues. 9 
2.2 Other cell types 10 
The biliary epithelium is supported by a layer of connective tissue [19], containing fibroblasts 11 
and elastic fibers (Figure 1). The distal third of the CBD is also surrounded by a sheet of 12 
smooth muscle [9] (Figure 1). Although these ‘supportive’ cell types do not demonstrate 13 
properties specific to the biliary tree, they are important for the structural integrity and 14 
nourishment of the bile duct and may contribute towards the mechanical properties for bio-15 
engineered constructs.   16 
 17 
3. Materials 18 
The generation of bioengineered bile ducts requires incorporation of the cell types described 19 
above into suitable materials that can be fabricated into a tubular structure. In tissue 20 
engineering, a large variety of synthetic and biological materials can be used to produce 21 
scaffolds that are capable of maintaining a population of cells in vitro or in vivo [20]. The choice 22 
of appropriate material(s) for generating a suitable tubular matrix requires balancing a number 23 
of parameters. For a given tube radius and wall thickness, the elastic and plastic properties of 24 
the tube wall material are important for supporting the cells and maintaining an unobstructed 25 
lumen for drainage of bile. The biocompatibility of the scaffold is not only essential for the 26 
viability of the cells in the tube [21], but also to prevent, or at least minimize, the inflammatory 27 
response that is inherently associated with surgery and transplantation of tissues [22]. Control 28 
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of this inflammatory response is particularly critical for bile ducts, as it can otherwise lead to 1 
fibro-inflammatory strictures and ultimately occlusion of the lumen [23], [24]. Finally, a material 2 
which is bioresorbable is desirable since it permits eventual remodeling and replacement of 3 
the scaffold with native cells and tissue [25]. 4 
As expected, most materials fail to meet all the necessary requirements outlined above. 5 
Synthetic polymers, for example, whilst mechanically robust and easily processed into three-6 
dimensional (3D) structures [26], often lack the necessary biocompatibility and resorbability 7 
[25]. Nonetheless, synthetic polymers are used to form uniaxial tubular structures (particularly 8 
in the field of vascular grafts) including materials such as polyglycolic acid (PGA), polylactic 9 
acid (PLA), polyurethane, poly(ε-caprolactone) (PCL) [27], expanded polytetrafluoroethylene 10 
(PTFE) [28], polyhydroxyalkanoates (PHA) and polyhydroxybutyrate (PHB) [29]. These 11 
synthetic polymer scaffolds are processed into a range of structures, demonstrate varying 12 
degrees of biocompatibility, and have degradation periods which can be tuned from a few 13 
weeks to years [29]. Biological materials, in comparison, are superior for cellular activity and 14 
their ability to be remodeled by cellular processes. However, their use can be constrained by 15 
their mechanical properties [26] and processing requirements (such as denaturation of 16 
proteins by high temperatures) [30], [31]. Some examples of tubular scaffolds fabricated from 17 
such biological polymers include collagen [18], collagen-agarose [32], and collagen 18 
membranes [33]. Hybrid scaffolds, such as tubes made from a polypropylene mesh and 19 
collagen sponge have also been produced [34]. 20 
 21 
4. Fabrication Techniques 22 
There are a number of possible methods to fabricate the materials described earlier into 23 
bioengineered patent tubular bile ducts. These include rolling of a polymeric sheet, molding, 24 
3D printing techniques, electrospinning, freeze-drying, and cellular self-assembly approaches. 25 
The simplest method for fabricating a uniaxial tube is to roll a polymeric sheet and suture along 26 
its length. While making large-scale tubes is relatively simple using this approach, use of 27 
suture material, even if absorbable, along the length of the native bile duct can lead to fibrosis 28 
7 
 
and strictures; portoenterostomy biliary reconstruction thus remains the current optimal 1 
treatment for iatrogenic bile duct injury [35][36]. 2 
Polymers can be molded to form a variety of structures, including tubes [37]. This method has 3 
the key advantage that, at least in the case of biological polymers, cells can be seeded into 4 
the precursor polymer solution providing a method for incorporating cells inside a dense 5 
scaffold [38], [39]. Alternatively, many polymers can be 3D printed, wherein a structure is 6 
constructed layer-by-layer, via a number of different techniques [40]–[42]. This enables 7 
complex architectures with very fine and reproducible features to be fabricated. However, we 8 
note that 3D printing includes a wide range of different approaches and there are particular 9 
challenges associated with each of these additive techniques [40], [41]. For example, 10 
extrusion-based 3D printing struggles in producing overhanging features and small-diameter 11 
tubes can collapse during fabrication [43]. 12 
Electrospinning operates by drawing out a narrow polymeric jet electrostatically [44], [45]. The 13 
solvent containing the polymer evaporates en route and a solid polymeric fiber is deposited 14 
on rotating collector, which can be used to form tubular structures consisting of a dense fibrous 15 
mesh [44]. This yields a mechanically robust tube, although the walls of the tube consist of a 16 
high density of polymer, making cellular infiltration difficult [45]. 17 
Freeze-drying involves freezing and dehydrating a polymer solution to produce a macro-18 
porous sponge architecture [46][26][33]. This allows seeded cells to penetrate deep inside the 19 
scaffold and be maintained in a bioreactor, which is advantageous when forming structured 20 
tissue. However, the high porosity of the scaffold makes them difficult to use as a conduit for 21 
fluid such as bile. Indeed, in the context of biliary reconstruction, bile leakage through the wall 22 
of porous scaffolds leads to biliary peritonitis [18]. Nevertheless, culturing the scaffolds in vitro 23 
can allow cells to fill the pores within the matrix material to form a more robust and 24 
impermeable tubular structure [47]. One notable method involves rolling a polyester felt sheet 25 
into a tube between two concentric cylinders and filling the spacing with polyglycolic acid 26 
(PGA) or polyL-lactic acid (PLLA) [47]. Using freeze-drying techniques, the solvent is then 27 
removed and the scaffold seeded with cells, which can penetrate deep into the scaffold [47]. 28 
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Finally, it is possible to produce tubular structures with self-assembled cell sheets, bioprinting, 1 
and other scaffold-free approaches in which cells are deposited directly to build a 3D structure 2 
[48], [49]. However, these generally produce structures that are mechanically very weak and 3 
require significant culture in vitro if to be used as a replacement conduit or vessel [26], [48].  4 
Importantly, for most materials and fabrication processes described, cells cannot be loaded 5 
into the construct during the fabrication process since the processing environment is typically 6 
too harsh and results in loss of cell viability (e.g. due to toxic chemicals, organic solvents, 7 
acidity or high temperature). Cells are therefore usually loaded after processing of the scaffold 8 
is complete via in vitro culturing techniques, such as with a bioreactor system, or by surgically 9 
implanting the scaffold as an acellular construct and allowing for migration of native cells and 10 
blood vessels.  11 
 12 
5. Vascular supply 13 
Bile ducts are very sensitive to ischemia [19], [50]–[52]. Indeed, inadequate blood supply 14 
through branches of the hepatic artery and peribiliary vascular plexus results in ischemic 15 
cholangiopathy, which constitutes one of the most common complications following liver 16 
transplantation [4], [52]. Consequently, the supply of oxygen and nutrients through an 17 
adequately vascularized stroma is essential for the long term survival of bioengineered bile 18 
ducts.  19 
However, the generation of vascular networks remains a key outstanding challenge in tissue 20 
engineering for the fabrication of thick tissue constructs and tissues with thickness greater 21 
than 400 μm require conduits for the delivery of metabolites and the removal of waste products 22 
[37]. Without such a system, highly populated cellularized constructs maintain inadequate 23 
metabolic activity, can form necrotic regions, and are limited in functionality.  24 
To address this challenge, multiple vascularization methods have been devised and can be 25 
classified in two main categories: Cellular co-culture systems and vascular network formation 26 
by materials processing. While the generation of vascular networks is outside the scope of 27 
this review, the key approaches and challenges are summarized below. 28 
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In cellular co-culture systems, capillary networks are formed through seeding of endothelial 1 
and supporting cell types onto [53] or inside [54] a hydrogel construct.   Prior to in vivo 2 
implantation, cells can be induced to form capillary-like structures [55] which, when the 3 
construct is surgically implanted, integrate into the native vasculature and can permit perfusion 4 
with blood [56]. A tissue construct that has been ‘pre-vascularized’ to form capillary-sized 5 
vessels is advantageous over an acellular construct, as the interconnecting network will rapidly 6 
integrate with the host vasculature and adapt dynamically to the metabolic requirements of 7 
the tissue. However, co-culture systems such as this require biologically-active polymers, such 8 
as collagen and fibrin, usually in low concentrations and with limited crosslinking, which limits 9 
the mechanical strength of the scaffold. Furthermore, incorporation of other signaling factors, 10 
such as VEGF and bFGF, may also be required in order to form vessels. This greatly limits 11 
the choice of materials that can be used for the replacement bile duct. Importantly, capillary 12 
networks cannot be surgically anastomosed to existing vessels and therefore require some 13 
time to form connections with the native vasculature. 14 
Vascular network formation via processing of biomaterials is an active field of research [43] 15 
that utilizes a variety of methods including needle molding [57], soft lithography [58], and a 16 
range of 3D printing-based approaches [39], [59]–[61]. This potentially enables large cell 17 
populations to be maintained in a metabolically active state in the scaffold from the outset, 18 
aiding cellular remodeling of the scaffold and cell survival. 19 
 20 
6. Advances in the generation of bioengineered bile ducts 21 
The advances described above have set the foundation for the generation and transplantation 22 
of the first bioengineered bile ducts. So far, 3 different approaches for the development of 23 
engineered bile ducts have been described (Table 1); the generation of acellular tubular 24 
constructs, the generation of bioengineered tubes populated by bone marrow cells (BMCs), 25 
and the generation of functional bioengineered tubes populated by human cholangiocytes 26 
[18], [27], [32], [62]–[69].  27 
6.1. Acellular constructs 28 
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The challenges in culturing cholangiocytes until recently have led to the use of multiple 1 
acellular constructs for bile duct repair or replacement [27], [32], [62]–[69]. More specifically, 2 
collagen, small intestinal submucosa, and human amnion combined with a polyglycolic acid 3 
(PGA) mesh have been used as bio-degradable scaffolds to successfully repair CBD wall 4 
defects [33], [65], [67], [68]. In all cases the scaffolds were completely absorbed and replaced 5 
by a healthy, epithelized and vascularized wall indistinguishable from the native CBD [33], 6 
[65], [67], [68]. These studies paved the way and provided invaluable information for the 7 
generation of tubular constructs; however the clinical applications of CBD patches remain 8 
somewhat limited mainly to the repair of iatrogenic CBD wall defects. 9 
To address CBD strictures or obliterating disorders such as biliary atresia, acellular tubular 10 
constructs were developed using multiple materials [32], [33], [62], [63], [65]–[67], [69]. Some 11 
of the first studies used scaffolds based on human tissue such as amnion and vein grafts 12 
[66][67]. These initial attempts were complicated by bile leak and strictures [66], [67], failing to 13 
provide adequate CBD drainage in the absence of a biliary stent [66]. However, subsequent 14 
attempts using PGA, PCL and PLA, and collagen tubes coated with agarose gel in dogs, pig 15 
and guinea pig models have been more successful [27], [32], [62], [63]. These studies 16 
demonstrated re-absorption of the biodegradable scaffolds and replacement by a vascularized 17 
and epithelized CBD wall, almost indistinguishable from the animal’s native CBD [66], [67]. 18 
However, these approaches also have limitations. The use of PGA scaffolds resulted in foreign 19 
body reaction early on, which was resolved by 8 months; while 55% of the animals were 20 
complicated by bile leak, cholangitis or biliary obstruction [63]. Cholangiography revealed CBD 21 
dilatation in the surviving animals but no stricture or abnormalities in liver function [63]. The 22 
use of collagen tubes resulted in epithelized tubes but with lower expression of biliary markers 23 
compared to the native CBD cholangiocytes [32], [62]. PCL/PLA tubes were associated with 24 
thickening of the neo-CBD connective tissue at 6 months [27]. Furthermore, the surgical 25 
approach used was the equivalent of a choledochoduodenostomy with the distal end of the 26 
PCL/PLA construct anastomosed to the duodenum rather than an end-to-end anastomosis to 27 
the distal CBD and the presence or absence of biliary tree dilatation was not assessed with 28 
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cholangiography [27]. Despite these limitations, the use of PCL/PLA is associated with the 1 
best outcomes described for an acellular construct. Finally, Polytetrafluoroethylene (PTFE) 2 
vascular grafts have also been used [69]; however, these resulted in asymptomatic bile duct 3 
dilatation, the animals were followed up for 8 days and no histological analyses of the grafts 4 
was performed [69]. 5 
6.2. BMC-populated constructs 6 
Despite the promising results from the use of acellular tubes in animals, these constructs are 7 
not functional at the time of transplantation and it is possible that they might not be as readily 8 
populated by human cholangiocytes due to intra-species variation between pig and human. 9 
More importantly, all the studies using acellular constructs which were outlined in the previous 10 
section were performed in healthy animals. However, it is not clear if re-epithelization with 11 
native cholangiocytes can take place as rapidly or effectively following transplantation of an 12 
engineered conduit into a diseased/pathological niche. Consequently, while the incorporation 13 
of cholangiocytes into the scaffold may seem unnecessary in normal animals, this may not be 14 
the case in diseased states. 15 
 To address this challenge, PCL/PLA tubes seeded with Bone Marrow Cells (BMCs) were 16 
transplanted in pigs anticipating differentiation of the BMCs into cholangiocytes [27]. The BMC 17 
populated tubes were compared to acellular transplanted PCL/PLA constructs. However, no 18 
difference in animal survival, liver function or histology was observed between the two groups 19 
[27]; while survival and differentiation of BMCs into cholangiocytes was not demonstrated [27].  20 
6.3. Constructs populated with human cholangiocytes 21 
More recently, densified collagen tubes populated with primary extrahepatic cholangiocyte 22 
organoids (ECOs) were used to generate functional bio-engineered bile ducts in vitro 23 
exhibiting GGT and ALP activity [18]. These tubes were subsequently transplanted into 24 
immune compromised mice using end-to-end anastomosis and replaced the native CBD of 25 
these animals [18]. Following transplantation, the lumen of the constructs remained populated 26 
by human cholangiocytes retaining the expression of structural (CK7) and functional (CFTR) 27 
biliary markers, as well as GGT and ALP activity, while the patency of the biliary tree was 28 
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confirmed using Magnetic Resonance Cholangiopancreatography (MRCP) and 1 
cholangiogram [18]. Considered collectively, these studies suggest that the transplantation of 2 
cholangiocyte-populated tubular scaffolds could represent an ideal therapeutic approach for 3 
cholangiopathies characterized by defects in bile duct formation and regeneration, such as 4 
biliary atresia. 5 
 6 
7. Future directions and conclusion 7 
Despite significant recent advances in the field of bile duct engineering, several challenges 8 
remain. There is a need to address whether cholangiocytes are required for the generation of 9 
functional human bile duct constructs or if the use of acellular constructs to repair or replace 10 
diseased, damaged or absent bile ducts could have equally good outcomes through 11 
spontaneous cellularization and vascularization in vivo. However, due to intra-species 12 
variation and differences in the potential for biliary regeneration between healthy and disease 13 
state, it may be difficult to address this question definitely without robust human clinical trials 14 
or transplantation of acellular constructs in animal models of bile duct injury. An additional 15 
requirement and outstanding challenge for translation to human studies is the need to use 16 
Good-Manufacturing-Practice (GMP) materials and cells. Furthermore, the generation of 17 
human-sized cellularized bile ducts may require the development of pre-vascularized 18 
constructs to ensure delivery of oxygen and nutrients to the cholangiocytes and other cell 19 
populations. Finally an alternative to the generation of engineered tubular constructs, could 20 
entail repopulating decellularized bile ducts with human cholangiocytes and this approach has 21 
been used with very good results for the repopulation of decellularized human liver scaffolds 22 
[70], [71].   23 
In conclusion, there is a pressing clinical need for the development of bio-engineered bile 24 
ducts and recent studies have demonstrated proof-of-principle for the feasibility of achieving 25 
this goal. Current advances in regenerative medicine, cell culture systems, materials, and 26 
fabrication methods provide a unique set of resources for overcoming the remaining 27 
challenges.  28 
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Figure legends 1 
 2 
Figure 1 3 
Schematic representation of the micro-anatomy of the bile duct. A monolayer of 4 
cholangiocytes is supported by a layer of connective tissue and a smooth muscle layer best 5 
identified in the distal end of the common bile duct, while oxygen and nutrients are provided 6 
through the peri-biliary plexus vessels. 7 
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Table 1. Comparison of approaches to bioengineering the bile duct. 2 
Cells Scaffold
Synthetic/ 
Biological
Animal Advantages Limitations
Post-operative 
follow up
Authors Year
Acellular Collagen membrane Biological Pig Bioabsorbable, allows for cellular ingrowth Limited to patch 0.5 - 4 months Tao, L. et al.  [33] 2015
Acellular Collagen membrane Biological Pig Bioabsorbable, allows for cellular ingrowth Limited to patch 1 - 3 months Li, Q. et al.  [68] 2012
Acellular Collagen sponge and polypropylene mesh Hybrid Dog
Successful re-epithelialization of the graft, 
allows for cellular ingrowth
Non-resorbable, 
biliary strictures
1 - 12 months Nakashima, S. et al.  [34] 2007
Acellular Collagen tube coated with agarose hydrogel Biological
Guinea 
Pig
Successful re-epithelialization of the graft, 
bioabsorbable, allows for cellular ingrowth
Reduced expression of 
biliary markers in neo-duct, 
non-resorbable
0.5 - 6 months Alonso, A.J.P. et al.  [32] 2013
Acellular
Proprietary mesh of polyglycolic acid 
and trimethylene carbonate
Synthetic Dog Bioabsorbable, allows for cellular ingrowth
Foreign body reaction,
obstruction, cholangitis
6 - 12 months Nau, P. et al.  [63] 2011
Acellular 
Expanded polytetrafluoroethyelene 
or woven Dacron
Synthetic Dog Allows for cellular ingrowth
Obstruction and migration, 
non-resorbable
6 weeks
Mendelowitz, D.S. 
and Beal, J.M. [28]
1982
Whole tissue
Degradable stent of poly[sebacic acid-co-
(1,3-propanediol)-co-(1,2-propanediol)] 
with autologous tissue around stent
Hybrid Pig Bioabsorbable
Fibrosis at the site of 
anastomosis and mildly 
abnormal liver function (GGT)
1 - 4 months Liang, Y. et al.  [64] 2012
Whole tissue Autologous vein graft Biological Dog Autologous graft Bile leak and strictures 2 - 12 months Wittrin, G. et al.  [72] 1978
Whole tissue Collagen-based small intestinal submuscosa Biological Dog Autologous graft
Strictures, bile leak, 
limited to patch
0.5 - 5 months Rosen, M. et al.  [65] 2002
Whole tissue Human amnion with polyglyolic acid mesh Hybrid Pig Autologous graft Bile leak and strictures 1 - 4 months Scudamore, C.H. et al.  [67] 1988
Whole tissue Autologous vein graft and silicon stent Hybrid Pig Autologous graft Strictures - stenting required 2 - 12 months Cushieri, A. et al.  [66] 1983
Autologous 
bone marrow 
cells (BMCs)
Polycaprolactone and polylactic acid 
copolymer, 
reinforced with polyglycolic acid fibers
Synthetic Pig
Successful re-epithelialization of the graft, 
allows for cellular ingrowth, bioabsorbable
Lengthy process, contribution 
of BMCs unclear
6 months Miyazawa, M. et al.  [27] 2004
Primary human 
cholangiocytes
Densified collagen gel Biological Mouse
Successful epithelialization of the graft 
with human cells, high functionality, 
allows for cellular ingrowth, bioabsorbable
Small animal model 1 month Sampaziotis, F. et al.  [18] 2017
